Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature

 

 Permissions and Reprints

ABSTRACT

Current guidelines for venous thromboembolism (VTE) primary prophylaxis are based on randomized clinical trials that exclude subjects at a potentially high bleeding risk. Thus no specific recommendation/algorithm for pharmacological prophylaxis in patients with thrombocytopenia and/or platelet dysfunction is available. Because at least 25% of subjects admitted to medical departments exhibit these conditions, information on this subject is provided here to optimize their VTE prophylaxis. Low platelet number/function and clotting abnormalities are common in patients with liver cirrhosis. However, these patients have a high incidence of portal and idiopathic venous thromboses, implying that cirrhotic coagulopathy does not protect against thrombosis. At variance with severe thrombocytopenia (< 50,000/μL), mild/moderate thrombocytopenia (> 50,000/μL) should not interfere with VTE prevention decisions. In severe thrombocytopenia, prophylaxis should be considered on an individual basis, however. In patients with antiphospholipid antibodies and thrombocytopenia, a thrombotic tendency is usually associated rather than a bleeding risk. VTE prophylaxis in high-risk conditions is thus suggested in these patients. Except in cases with contraindications to anticoagulation, antithrombotic prophylaxis should be always considered in hospitalized cancer patients with thrombocytopenia, especially in those with hematologic malignancies and multiple VTE risk factors. Aspirin treatment is not as effective as heparins in lowering the risk of VTE. Studies in stroke suggest that thromboprophylaxis with heparins is safe in patients with ischemic stroke undergoing aspirin treatment. The need for VTE prophylaxis in patients on chronic treatment with aspirin and/or clopidogrel should be evaluated after assessing the individual risk-benefit ratio.

REFERENCES

• 1 Anderson Jr F A, Wheeler H B, Goldberg R J et al.. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.  Arch Intern Med. 1991;  151 (5) 933-938
  CrossrefPubMedGoogle Scholar
• 2 Rubinstein I, Murray D, Hoffstein V. Fatal pulmonary emboli in hospitalized patients. An autopsy study.  Arch Intern Med. 1988;  148 (6) 1425-1426
  CrossrefPubMedGoogle Scholar
• 3 Di Minno G, Mannucci P M, Tufano A First Ambulatory Screening On Thromboembolism (fast) Study Group et al. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism.  J Thromb Haemost. 2005;  3 (7) 1459-1466
  CrossrefPubMedGoogle Scholar
• 4 Samama M M, Cohen A T, Darmon J-Y et al.. A comparison of enoxaparin with placebo for the prevention of VTE in acutely ill medical patients. Prophylaxis in Medical Patients Study Group.  N Engl J Med. 1999;  341 (11) 793-800
  CrossrefPubMedGoogle Scholar
• 5 Leizorovicz A, Cohen A T, Turpie A G, Olsson C G, Vaitkus P T, Goldhaber S Z. PREVENT Medical Thromboprophylaxis Study Group . Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.  Circulation. 2004;  110 (7) 874-879
  CrossrefPubMedGoogle Scholar
• 6 Cohen A T, Davidson B L, Gallus A S ARTEMIS Investigators et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.  BMJ. 2006;  332 (7537) 325-329
  CrossrefPubMedGoogle Scholar
• 7 Geerts W H, Bergkvist D, Pineo G F et al.. Prevention of venous thromboembolism: ACCP Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 (6, Suppl) 381S-453S
  CrossrefPubMedGoogle Scholar
• 8 Tapson V F, Decousus H, Pini M IMPROVE Investigators et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.  Chest. 2007;  132 (3) 936-945
  CrossrefPubMedGoogle Scholar
• 9 Monreal M, Kakkar A K, Caprini J A RIETE Investigators et al. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry.  J Thromb Haemost. 2004;  2 (11) 1892-1898
  CrossrefPubMedGoogle Scholar
• 10 Cohen A T, Tapson V F, Bergmann J F ENDORSE Investigators et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.  Lancet. 2008;  371 (9610) 387-394
  CrossrefPubMedGoogle Scholar
• 11 Lippi G, Favaloro E J, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis.  Semin Thromb Hemost. 2011;  37 (3) 237-251
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Prandoni P, Samama M M. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.  Br J Haematol. 2008;  141 (5) 587-597
  CrossrefPubMedGoogle Scholar
• 13 Maynard G A, Morris T A, Jenkins I H et al.. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model.  J Hosp Med. 2010;  5 (1) 10-18
  PubMedGoogle Scholar
• 14 Senzolo M, Sartori M T, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?.  HPB (Oxford). 2009;  11 (6) 459-464
  CrossrefPubMedGoogle Scholar
• 15 Northup P G, Caldwell S H. New concepts of coagulation and bleeding in liver disease.  Intern Emerg Med. 2010;  5 (1) 3-6
  CrossrefPubMedGoogle Scholar
• 16 Tripodi A, Primignani M, Mannucci P M. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged.  Intern Emerg Med. 2010;  5 (1) 7-12
  CrossrefPubMedGoogle Scholar
• 17 Northup P G, McMahon M M, Ruhl A P et al.. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism.  Am J Gastroenterol. 2006;  101 (7) 1524-1528 quiz 1680
  CrossrefPubMedGoogle Scholar
• 18 Oka K, Tanaka K. Intravascular coagulation in autopsy cases with liver diseases.  Thromb Haemost. 1979;  42 (2) 564-570
  PubMedGoogle Scholar
• 19 Wanless I R, Wong F, Blendis L M, Greig P, Heathcote E J, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension.  Hepatology. 1995;  21 (5) 1238-1247
  CrossrefPubMedGoogle Scholar
• 20 Amitrano L, Guardascione M A, Ames P R. Coagulation abnormalities in cirrhotic patients with portal vein thrombosis.  Clin Lab. 2007;  53 (9–12) 583-589
  PubMedGoogle Scholar
• 21 Søgaard K K, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen H T. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study.  Am J Gastroenterol. 2009;  104 (1) 96-101
  CrossrefPubMedGoogle Scholar
• 22 Tripodi A, Primignani M, Chantarangkul V et al.. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis.  Gastroenterology. 2009;  137 (6) 2105-2111
  CrossrefPubMedGoogle Scholar
• 23 Kaushansky K. Thrombopoietin.  N Engl J Med. 1998;  339 (11) 746-754
  CrossrefPubMedGoogle Scholar
• 24 Adinolfi L E, Giordano M G, Andreana A et al.. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis.  Br J Haematol. 2001;  113 (3) 590-595
  CrossrefPubMedGoogle Scholar
• 25 Giannini E, Borro P, Botta F et al.. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis.  J Hepatol. 2002;  37 (5) 572-577
  CrossrefPubMedGoogle Scholar
• 26 Wang C S, Yao W J, Wang S T, Chang T T, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection.  Clin Infect Dis. 2004;  39 (6) 790-796
  CrossrefPubMedGoogle Scholar
• 27 Lisman T, Bongers T N, Adelmeijer J et al.. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity.  Hepatology. 2006;  44 (1) 53-61
  CrossrefPubMedGoogle Scholar
• 28 Afdhal N, McHutchison J, Brown R et al.. Thrombocytopenia associated with chronic liver disease.  J Hepatol. 2008;  48 (6) 1000-1007
  CrossrefPubMedGoogle Scholar
• 29 Amitrano L, Guardascione M A, Menchise A et al.. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.  J Clin Gastroenterol. 2010;  44 (6) 448-451
  PubMedGoogle Scholar
• 30 Lyman G H, Khorana A A, Falanga A American Society of Clinical Oncology et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.  J Clin Oncol. 2007;  25 (34) 5490-5505
  CrossrefPubMedGoogle Scholar
• 31 Tosetto A, Balduini C L, Cattaneo M Italian Society for Haemostasis and Thrombosis et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).  Thromb Res. 2009;  124 (5) e13-e18
  CrossrefPubMedGoogle Scholar
• 32 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism.  Lancet Oncol. 2005;  6 (6) 401-410
  CrossrefPubMedGoogle Scholar
• 33 Caine G J, Stonelake P S, Lip G YH, Kehoe S T. The hypercoagulable state of malignancy: pathogenesis and current debate.  Neoplasia. 2002;  4 (6) 465-473
  CrossrefPubMedGoogle Scholar
• 34 Lee A Y, Levine M N. Venous thromboembolism and cancer: risks and outcomes.  Circulation. 2003;  107 (23, Suppl 1) I17-I21
  PubMedGoogle Scholar
• 35 Caine G J, Stonelake P S, Rea D, Lip G YH. Coagulopathic complications in breast cancer.  Cancer. 2003;  98 (8) 1578-1586
  CrossrefPubMedGoogle Scholar
• 36 Heit J A, Silverstein M D, Mohr D N, Petterson T M, O'Fallon W M, Melton III L J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.  Arch Intern Med. 2000;  160 (6) 809-815
  CrossrefPubMedGoogle Scholar
• 37 Falanga A, Donati M B. Pathogenesis of thrombosis in patients with malignancy.  Int J Hematol. 2001;  73 (2) 137-144
  CrossrefPubMedGoogle Scholar
• 38 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res. 2001;  102 (6) V215-V224
  CrossrefPubMedGoogle Scholar
• 39 Baron J A, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer.  Lancet. 1998;  351 (9109) 1077-1080
  CrossrefPubMedGoogle Scholar
• 40 Rickles F R, Falanga A, Montesinos P, Sanz M A, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?.  Thromb Res. 2007;  120 (Suppl 2) S99-S106
  CrossrefPubMedGoogle Scholar
• 41 Herishanu Y, Misgav M, Kirgner I, Ben-Tal O, Eldor A, Naparstek E. Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens.  Leuk Lymphoma. 2004;  45 (7) 1407-1411
  CrossrefPubMedGoogle Scholar
• 42 Cortelezzi A, Moia M, Falanga A CATHEM Study Group et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study.  Br J Haematol. 2005;  129 (6) 811-817
  CrossrefPubMedGoogle Scholar
• 43 Lim W. Antiphospholipid antibody syndrome.  Hematology Am Soc Hematol Educ Program. 2009;  233-239
  PubMedGoogle Scholar
• 44 Metjian A, Lim W. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?.  Hematology Am Soc Hematol Educ Program. 2009;  247-249
  PubMedGoogle Scholar
• 45 Kitchens C S. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC).  Hematology Am Soc Hematol Educ Program. 2009;  240-246
  PubMedGoogle Scholar
• 46 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 (7329) 71-86
  CrossrefPubMedGoogle Scholar
• 47 Douketis J D, Berger P B, Dunn A S American College of Chest Physicians et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 (6, Suppl) 299S-339S
  CrossrefPubMedGoogle Scholar
• 48 Biondi-Zoccai G GL, Lotrionte M, Agostoni P et al.. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease.  Eur Heart J. 2006;  27 (22) 2667-2674
  CrossrefPubMedGoogle Scholar
• 49 Di Minno M ND, Prisco D, Ruocco A L, Mastronardi P, Massa S, Di Minno G. Perioperative handling of patients on antiplatelet therapy with need for surgery.  Intern Emerg Med. 2009;  4 (4) 279-288
  CrossrefPubMedGoogle Scholar
• 50 Kamphuisen P W, Agnelli G. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?.  Thromb Res. 2007;  119 (3) 265-274
  CrossrefPubMedGoogle Scholar
• 51 Chassot P G, Delabays A, Spahn D R. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction.  Br J Anaesth. 2007;  99 (3) 316-328
  CrossrefPubMedGoogle Scholar

Antonella TufanoM.D. Ph.D. 

Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine

“Federico II” University of Naples, Naples, Italy

Email: aTufano@uninsc.it